Trials / Completed
CompletedNCT04402112
Efficacy and Safety of Pitavastatin in a Real-world Setting
Efficacy and Safety of Pitavastatin in a Real-wOrld Setting: Observational Study Evaluating saFety in Patient With Pitavastatin for Lipid Lowering Therapy in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28,343 (actual)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The prospective, observational, non-comparative trial in South Korea was designed to evaluate the efficacy and safety of pitavastatin (Livalo) in clinical practice in 28,343 patients.
Detailed description
This study was conducted in 893 facilities in Korea from 2 Apr 2012 to 1 Apr 2017. This study was designed to administer 1mg, 2mg, or 4mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pitavastatin | 1mg, 2mg, or 4mg, Once a day, at least 8 weeks |
Timeline
- Start date
- 2012-04-02
- Primary completion
- 2017-04-01
- Completion
- 2017-08-01
- First posted
- 2020-05-26
- Last updated
- 2021-04-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04402112. Inclusion in this directory is not an endorsement.